Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...

Anecdotal evidence suggests that low, nonhallucinogenic doses of psychedelics can reduce symptoms of schizophrenia and psychosis. 5-Methoxy-N,N-dimethyltryptamine (5-MeO–DMT) has demonstrated ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Both companies have zeroed in on a disorder that affects millions of people with the potential for huge financial success.

He said: Get the latest updates on One Championship Rankings at Sportskeeda and more "We [my wife and I] received Ibogaine and 5-MeO-DMT as well in order to understand how each operation ...

NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health treatments with a current market capitalization of $243 million, announced positive ...

The money is also earmarked for a phase 1 dose-ranging study on an intranasal formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a psychedelic compound found in plants and at least one ...

Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of GH Research in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio ...

BeckleyPsytech近日宣布，其2a期研究结果显示，在研疗法BPL-003单次给药后，可持续3个月显著降低中至重度酒精使用障碍（AUD）患者的酒精摄入量和重度饮酒天数（HDDs），并为患者带来持久且有意义的改善。值得一提的是，大多数患者在给药 ...